Title: Study to Determine Relapse and Mortality Rates in Tuberculosis Cases and their Epidemiological Correlates: A Historical Cohort Study

Authors: Dr Atul Gupta, Dr Shavinder Singh, Dr Rajesh Isaac, Dr Deepshikha Kamra

 DOI:  https://dx.doi.org/10.18535/jmscr/v4i12.76

Abstract

Background: India is the country with the highest burden of TB. The World Health Organization (WHO) statistics for 2015 give an estimated incidence figure of 2.2 million cases of TB for India out of a global incidence of 9.6 million. The estimated TB prevalence in India for 2015 is 2.5 million.

Aims and Objectives

1.      To determine the median relapse rate and to identify risk factors associated with TB relapse

2.      To determine the mortality rate and its epidemiological correlates.

Methodology: All the diagnosed cases of  tuberculosis over the period from Jan 2000 to Dec 2013, in the field practice areas of the Department of Community Medicine were followed up at their residences. 278 cases could be interviewed at home, and details were obtained about 14 deaths.  Their history after the completion of their last course of ATT was determined, along with relevant history of disease till date using a structured questionnaire. Those who could not be located or contacted after two visits were excluded from the study. Data was entered into a Epidata Entry database and analyzed by Epidata Analysis 2.2.2 and EpiInfo 3.5.4 software.

Statistical Analysis: The percentages were used to describe relapse rates. Survival analysis was used to determine median relapse rates.

 Results: 278 treated patients were available for interview. Fourteen deaths occurred among cases. Out of total 292 tuberculosis cases, 36 cases relapsed.

Out of those relapsed cases, 30 were on DOTs and 6 were on Non-DOTs regimen, but the difference was not statistically significant (p=0.0723). Available data showed a high relapse rate of 12.3%, exceeding the acceptable norm of less than five percent. Males were twice at the risk of relapsing as compared to females and it was statistically significant (p=0.0099). Mortality in males was six times higher than females (p=0.0029). Mortality in cases who were on DOTs regimen was higher as compared to cases who were on the Non-DOTs regimen, but difference was not statistically significant (p=0.5602). An  association was seen between chronic alcoholics and cases who relapsed for the first time (p=0. 0000). The association was also seen between smokers and cases who relapsed for the first time (p=0.0000).

Conclusions: This retrospective cohort study revealed high relapse rates, above the recommended levels. Relapse rates were marginally higher among patients on DOTs as compared to non DOTs therapy. Mortality was six times higher in males as compared to females. Mortality rate was higher among patents on DOTs therapy as compared to non DOTs therapy. Measures to improve the compliance of DOTs therapy are urgently needed.

References

1.      “Global Tuberculosis Control 2015, WHO, Geneva, 2015 www.who.int/tb/public-ations/global_report/

2.      Nobel Foundation. The Nobel Prize in Physiology or Medicine 1905. [Cited 2010 Sep 10];Available from: URL:http://de.wikipedia.org/.../Simple:Nobel_Prize_in_Physiology_or_Medicine.

3.      Govt. of India. TB India 2011, RNTCP status report, Central TB Division. New Delhi: Ministry of Health and Family Welfare, Govt. of India; 2011.

4.      T. Santha, R. Garg, T. R. Frieden, V. Chandrasekaran, R. Subramani, P. G. Gopi, N.Selvakumar, S. Ganapathy, N Charles, J. Rajamma, P.R Narayanan. Risk factors associated with default, failure and death among tuberculosis patients treated in a DOTS Programme in Tiruvallur District, South India, 2000. International Journal of Tuberculosis and Lung Disease, 2002; 6(9): 780-788. Co

5.      World Health Organization. Treatment of tuberculosis guidelines. 4th ed. [accessed on May 27, 2012]. WHO/HTM/T-B/2009.420. Available from:http://whqlibdoc.who.int/publications/2010/9789241547833_eng.pdfSimilar

6.      Murray CJL, Lopez AD, editors. The global burden of disease. Cambridge:  Harvard University Press; 1996

7.      Cullinan P, Meredith SK. Deaths in adults with notified pulmonary  Tuberculosis 1983–5. Thorax 1991;46:347-350.       

8.      Glynn JR, Warndorff DK, Fine PEM, Munthali MM, Sichone W,  Ponnighaus M. Measurement and determinants of tuberculosis outcome in Karonga District, Malawi.Bull World HealthOrgan 1998;76:295-305       

9.      Pablos-Mendez A, Sterling TR, Frieden TR. Therelationship between delayed or incomplete treatment and all-cause mortality in patients with tuberculosis. JAMA 1996;276:1223-1228.     

10.  Walpola HC, Siskind V, Patel AM, Konstantions A, Derhy P. Tuberculosis-related  deaths in Queensland Australia, 1989–1998: characteristics and risk factors. Int J Tuberc and Lung Dis 2003;7:742-750.    

11.  National Tuberculosis Institute, Bangalore. Tuberculosis in a rural population  of  South India five-year epidemiological study. Bull World Health Organ 1974;51:473-488.   

12.  Gajalaxmi V, Peto R, Santhana krishnakanaka T, Jha P. Smoking and mortality from tuberculosis and other diseases in India: retrospective study of 43000 adult male deaths and 35000 controls. Lancet 2003;362:507–515.       

13.  Datta M, Radhamani MP, Selvaraj R, Paramasivan CN, Gopalan BN, Sudeendra CR, et al. Critical assessment of smear positive pulmonary tuberculosis patients after chemotherapy under the district tuberculosis programme. Tuber Lung Dis 1993;74:180-186.             

14.  WHO Tuberculosis Programme. Frame work for effective tuberculosis control. Geneva, Switzerland: World Health Organization; 1994. WHO document  WHO/TB/94. p. 179

15.  Didilescu C, Popescu G, Cioran N, Cocei H. [Mortality of tuberculosis in Romania, a marker for severity of the endemic]. Pneumol Buchar Rom. 2012 Sep; 61 (3): 150–2

16.  Characteristics and treatment outcomes of tuberculosis cases by risk groups, Japan, 2007–2010 | Uchimura | Western Pacific Surveillance and Response [Internet]. [Cited 2016 Jun 5]. Available from: http://ojs.wpro.who.int/ojs/index.php/wpsar/article/view/186/237

17.  Thomas A, Gopi PG, Santha T, Chandrasekaran V, Subramani R, Selvakumar N, et al. Predictors of relapse among pulmonary tuberculosis patients treated in a DOTS programme in South India. Int J Tuberc Lung Dis Off J Int Union Tuberc Lung Dis. 2005 May; 9 (5): 556–61.

18.  Batista JL, Albuquerque MFPM, Ximenes RAA, Rodrigues LC. Smoking  increases the risk of relapse after successful tuberculosis treatment.  International Journal of Epidemiology 2008;37:841–851

19.  Kolappan C, Gopi PG, Subramani R, Narayanan PR. Selected biological and behavioral risk factors associated with pulmonary tuberculosis. Int. Jour. Tuberc Lung Dis. 2007;11(9):999–1003.

20.  Joseph MR, Thomas RA, Nair S, Balakrishnan S, Jayasankar S. Directly observed treatment short course for tuberculosis. What happens to them in the long term? Indian J Tuberc. 2015 Jan; 62 (1): 29–35

21.  Soomro JA., Qazi HA., Factors Associated with relapsed tuberculosis in males and females: a    comparative study. Tanaffos. 2009; 8, 22-27

22.  Gustafson P., Gomes V. F., Vieira C. S., et al. Tuberculosis in Bissau: incidence and risk factors in an urban community in sub-Saharan Africa. International Journal of Epidemiology. 2004;33(1):163–172. doi: 10.1093/ije/dyh026. [PubMed].

23.  Srinath S, Sharath B, Santosha K, Chadha SS, Roopa S, Chander K, et al. Tuberculosis “retreatment others”: profile and treatment outcomes in the state of Andhra Pradesh, India. Int J Tuberc Lung Dis Off J Int Union Tuberc Lung Dis. 2011 Jan; 15 (1): 105–9.

Corresponding Author

Dr Atul Gupta

PG Resident, Dept. of Community Medicine,

Christian Medical College, Ludhiana